BioVie Inc. stocks have been trading up by 37.91 percent amid heightened optimism surrounding its latest Alzheimer’s therapy developments.
Click Here for a Millionaire's POV on Trading BIVI
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways Traders Should Watch
- Phase 2 SUNRISE-PD trial in early-stage Parkinson’s met its primary endpoint, with improved inflammatory and neurodegeneration biomarkers and better motor and non-motor outcomes versus placebo.
- Topline SUNRISE-PD data showed statistically significant gains on MDS‑UPDRS I–III and composite EPNIC‑115, with a placebo-like safety profile backing bezisterim’s risk/reward.
- Results support advancing bezisterim into a potentially pivotal Phase 3 trial, expanding BioVie’s neurodegenerative pipeline narrative.
- A new Schedule 13G disclosed a passive but notable beneficial ownership stake in BioVie Inc. (BIVI), signaling fresh outside confidence.
Live Update At 07:47:07 EDT: On Wednesday, August 19, 2026 BioVie Inc. stock [NASDAQ: BIVI] is trending up by 37.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
BIVI has been trading like a classic biotech story stock: heavy catalysts, sharp moves, and plenty of volatility. Over the last few weeks, BioVie Inc. ran from around $1.30–$1.40 into a spike high near $3.79 on 2026/08/12 before fading back toward the $1.00 zone. That kind of rip-and-fade shows exactly how traders crowd into headlines, then quickly take profits.
More recently, BIVI closed near $0.96 on 2026/08/18 after several red days from the $1.50–$1.60 area. From a chart standpoint, the stock has broken its short-term uptrend and is now fighting to hold psychological support around $1. For day traders, that’s a key line in the sand.
More Breaking News
- SMR Stock Slips As Analysts Slash NuScale Power Targets
- TNON Stock Jumps As Q2 Growth Collides With Cash Risk
- ENVX Stock Slides As CEO Exit And Soft Guidance Rattle Traders
- EYPT Stock Crashes On Duravyu Data But Catalysts Loom
Intraday, the 5‑minute tape shows how violent the action can be. On the catalyst day, BIVI ripped from roughly $1.47 at 04:00 to above $2.00 in minutes before grinding lower. That’s momentum-trading 101. Fundamentally, BioVie Inc. is early-stage: negative net income of about -$5.6M for the recent quarter, heavy R&D spend near $24.3M, and operating cash outflows around -$4.1M. The good news for traders tracking runway is that BIVI still shows roughly $9.0M in cash and minimal debt, with a current ratio above 3. That buys time, but not forever.
Why Traders Are Watching BIVI Now
The real reason BIVI is back on radar is not the balance sheet. It’s the science. BioVie Inc. reported positive Phase 2 SUNRISE-PD data for its Parkinson’s candidate bezisterim, and that kind of clear clinical win can reset how traders value a small-cap biotech overnight.
The company said SUNRISE-PD in early Parkinson’s met its primary endpoint, with improved biomarkers tied to inflammation and neurodegeneration. For biotech traders, biomarker confirmation matters because it suggests the drug is not just easing symptoms, but engaging the underlying disease biology. That’s the difference between a “maybe” story and a serious platform.
On top of that, BIVI highlighted statistically significant improvements versus placebo across both motor and non-motor symptoms, as captured by standard Parkinson’s scales like MDS‑UPDRS I–III and the composite EPNIC‑115 score. That tells traders these are not marginal gains buried in the data tables. They show up on the core measures neurologists actually use.
Equally important for risk-focused traders, BioVie Inc. reported a placebo-like safety profile. In early Parkinson’s, safety is non‑negotiable; patients are treated for years. So when BIVI says bezisterim paired efficacy signals with clean tolerability, it helps derisk the path toward a potentially pivotal Phase 3 trial.
There’s also a secondary signal: a fresh Schedule 13G filing shows a new or increased passive beneficial ownership stake in BIVI. While that filing alone doesn’t predict future price action, it tells traders at least one outside player found the risk/reward compelling enough to disclose a notable position after the SUNRISE-PD news. In a thinly traded name like BioVie Inc., that kind of interest can tighten the float and amplify future moves on any new headline.
Conclusion
For active traders, BIVI now sits at the intersection of strong news and shaky price action. BioVie Inc. just delivered what many small biotechs chase for years: a Phase 2 win with statistically significant efficacy, biomarker validation, and a clean safety profile in a large disease like early Parkinson’s. That lays the groundwork for a potentially pivotal Phase 3 and gives bezisterim real franchise optionality across neurodegeneration, not just a single narrow label.
At the same time, the chart reminds everyone how unforgiving the market is. BIVI spiked from the $1s to almost $4, then bled back under $1.20, showing that even great news doesn’t guarantee a straight-line uptrend. BioVie Inc. still burns cash, posts negative earnings, and relies on future capital to advance the pipeline. Any delay or disappointment in the Phase 3 path can hit the stock hard.
That’s where disciplined trading comes in. As Tim Sykes loves to remind his students, “The market doesn’t care about your opinion, only your risk management.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.”. For BIVI, that means treating it as a catalyst-driven biotech — study the SUNRISE-PD data, map key technical levels, respect liquidity, and always plan exits before entries. BioVie Inc. has given traders a real story to work with; now the edge comes from how well you trade it, not how much you believe in it.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.